Natera Launching Collaboration With Incyte for Phase 2 Trial to Treat Colorectal Cancer
MT Newswires Live
Nov 10
Natera (NTRA) said Tuesday it is launching a clinical collaboration with Incyte (INCY) for a phase 2 trial to potentially treat colorectal cancer.
The trial will evaluate Incyte's INCA33890 in patients with stage 2/3 colorectal cancer who have completed surgery and chemotherapy.
After chemotherapy, patients will get longitudinal testing with Natera's Signatera for up to 12 months, and those who test Signatera MRD-positive may be eligible for enrollment and treatment in the trial, according to the statement.
Additionally, Natera will also supply trial-matching services to support patient identification for enrollment based on their Signatera MRD status and other criteria, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.